Related Experiment Videos
Long-term versus short-term hearing aid benefit
R K Surr1, M T Cord, B E Walden
1Audiology & Speech Center, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
Journal of the American Academy of Audiology
|June 30, 1998
Summary
Hearing aid benefit from wide dynamic range compression (WDRC) amplification showed no significant change after one year of use. A six-week acclimatization period is sufficient for assessing hearing aid benefit in clinical trials.
Area of Science:
- Audiology
- Hearing Science
- Biomedical Engineering
Background:
- Hearing aid technology has advanced, with Wide Dynamic Range Compression (WDRC) offering improved audibility.
- Long-term adaptation to new hearing aid amplification strategies requires investigation.
- Previous studies suggest varying acclimatization periods for different hearing aid technologies.
Purpose of the Study:
- To compare hearing aid benefit at 6 weeks versus a minimum of 1 year post-fitting.
- To evaluate the long-term effectiveness of WDRC hearing aids.
- To determine if extended use alters perceived and measured hearing aid benefit.
Main Methods:
- Fifteen participants with mild-to-moderate sensorineural hearing loss were fitted binaurally with Resound BT2 WDRC hearing aids.
- The Profile of Hearing Aid Benefit (PHAB) and Connected Speech Test (CST) were administered at 6 weeks and after 1 year.
- Standard manufacturer programming and fitting protocols were employed.
Main Results:
- Significant aided benefit was observed for both the PHAB and CST at the 6-week assessment.
- No statistically significant changes in hearing aid benefit were found between the 6-week and 1-year assessments.
- Individual results indicated consistent benefit across the study duration.
Conclusions:
- A 6-week acclimatization period appears adequate for evaluating the benefits of this type of WDRC hearing aid.
- Long-term use does not significantly alter the measured benefit obtained from WDRC hearing aids.
- Findings support the use of shorter trial periods in clinical settings for WDRC amplification.